The HBP performance measures may further evolve on the basis of additional evidence, along with future focused updates and revisions to the 2017 Hypertension Clinical Practice Guidelines. ACC/AHA TASK FORCE MEMBERS Gregg C. Fonarow, MD, FACC, FAHA, Chair*; Biykem Bozkurt, MD, PhD, FACC*; Sandeep Das, MD, MPH*; Michael E. Hall, MD, MS, FAHA, FACC*; Hani Jneid, MD, FACC, FAHA*; Corrine Y. Jurgens, PhD, RN, ANP-BC, FAHA* ; Patricia Keegan, DNP, APRN, NP-C ; Rohan Khera, MD* ; Leo Lopez, MD, FACC ; Jeffrey W. Olin, DO, FACC, FAHA*; Manesh Patel, MD, FACC*; Faisal Rahman, BM BCh ; Matthew Roe, MD, FACC ; Alex Sandhu, MD, MS ; Randal J. Thomas, MD, MS, FACC, FAHA ; Muthiah Vaduganathan, MD, MPH ; Paul D. Varosy, MD, FACC ; Siqin Ye, MD, MS ; Boback Ziae- ian, MD, PhD, FACC STAFF American College of Cardiology Richard J. Kovacs, MD, FACC, President Timothy W. Attebery, MBA, FACHE, Chief Executive Officer William J. Oetgen, MD, MBA, FACC, FACP, Executive Vice President, Science, Education, Quality, and Publishing Lara Slattery, Team Lead/Division Vice President, Clinical Registry and Accreditation *American Heart Association Representative. Former Task Force member; current member during the writing effort. American College of Cardiology Representative. SM-9 Use of a single, standardized plan of care for all patients with HBP CDU Studies demonstrate that implementation of a plan of care for HBP can lead to sustained reduction of BP and attainment of BP targets over several years. SM-10 Use of performance and quality measures to improve quality of care for patients with HBP CDU A large observational study showed that a systematic approach to HBP control, including the use of performance measures, was associated with significant improvement in HBP control compared with historical control groups. *Including office, clinic, home, or ambulatory. 